BioMarin to Present at the Cowen Healthcare Conference in Boston

BioMarin to Present at the Cowen Healthcare Conference in Boston

SAN RAFAEL, Calif., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN), a global leader in the development and commercialization
of therapies for rare genetic diseases, today announced that Dan Maher, Senior
Vice President, Product Development will present at the Cowen and Company
34^th Annual Healthcare Conference on March 4^th at 11:20am ET. To access the
live webcast, please visit the Investor section of the BioMarin website,
www.BMRN.com. A replay will be archived on the site for at least one week
following the event.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
five approved products and multiple clinical and pre-clinical product
candidates. Approved products include VIMIZIM™ (elosulfase alfa) for MPS IVA;
Naglazyme® (galsulfase) for MPS VI; Aldurazyme® (laronidase) for MPS I, a
product which BioMarin developed through a 50/50 joint venture with Genzyme, a
Sanofi Company; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany and Firdapse® (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include PEG PAL (PEGylated
recombinant phenylalanine ammonia lyase), which is currently in Phase 3
clinical development for the treatment of PKU, BMN 673, a poly ADP-ribose
polymerase (PARP) inhibitor, which is currently in Phase 3 clinical
development for the treatment of germline BRCA breast cancer, BMN 701, a novel
fusion protein of insulin-like growth factor 2 and acid alpha glucosidase
(IGF2-GAA), which is currently in Phase 1/2 clinical development for the
treatment of Pompe disease, BMN 111, a modified C-natriuretic peptide, which
is currently in Phase 1 clinical development for the treatment of
achondroplasia, BMN 190, a recombinant human tripeptidyl peptidase-1 (rhTPP1)
for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2), a
form of Batten Disease, which is currently in Phase 1, BMN 270, an AAV-factor
VIII vector, for the treatment of hemophilia A and BMN 250, a novel fusion of
alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like
growth factor 2 (IGF2), for the treatment of MPS IIIB.

For additional information, please visit www.BMRN.com.

CONTACT: Investors:
         Traci McCarty
         BioMarin Pharmaceutical Inc.
         (415) 455-7558
        
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.